Cargando…

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lothstein, Leonard, Soberman, Judith, Parke, Deanna, Gandhi, Jatin, Sweatman, Trevor, Seagroves, Tiffany
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751225/ https://www.ncbi.nlm.nih.gov/pubmed/32430093 http://dx.doi.org/10.3727/096504020X15898794315356

Ejemplares similares

SAT-133 Breast Tumor Kinase (Brk/PTK6) Mediates Triple Negative Breast Cancer Cell Migration and Taxol Resistance via SH2 Domain-Dependent Activation of RhoA and AhR
por: Dwyer, Amy Renee, et al.
Publicado: (2020)

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
por: Velenosi, Thomas J., et al.
Publicado: (2022)

SUN-008 The Glucocorticoid Receptor Is Essential For TGFβ and p38 MAPK Mediated Cancer Phenotypes in Triple Negative Breast Cancer
por: Perez Kerkvliet, Carlos, et al.
Publicado: (2019)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis
por: Krutilina, Raisa I., et al.
Publicado: (2022)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
por: Ganapathi, R., et al.
Publicado: (1989)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Immunocompetence in adults: more than HIV negative
por: Zea-Vera, Andres Felipe
Publicado: (2016)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy
por: Zhou, Jingyi, et al.
Publicado: (2023)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer
por: Fatima, Iram, et al.
Publicado: (2017)

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2019)

ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models
por: Brooks, Danielle L. Peacock, et al.
Publicado: (2016)

Correction: The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer
por: Fatima, Iram, et al.
Publicado: (2018)

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer
por: McKenna, Matthew T., et al.
Publicado: (2017)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
por: Mentoor, Ilze, et al.
Publicado: (2021)

Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer
por: Lee, Kevin J, et al.
Publicado: (2021)

Epididymal research: more warp than weft?
por: Cooper, Trevor G
Publicado: (2015)

Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity
por: Shoukry, Heba Samy, et al.
Publicado: (2017)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
por: Wardhani, Bantari WK, et al.
Publicado: (2020)

Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study
por: Arora, Garhima, et al.
Publicado: (2021)

Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model
por: Dong, Hang, et al.
Publicado: (2023)

Comparative Evaluation of the Cytotoxicity of Doxorubicin in BT-20 Triple-Negative Breast Carcinoma Monolayer and Spheroid Cultures
por: Ncube, Keith N., et al.
Publicado: (2023)

Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
por: Price, Lauren S.L., et al.
Publicado: (2021)

HIF-Dependent CKB Expression Promotes Breast Cancer Metastasis, Whereas Cyclocreatine Therapy Impairs Cellular Invasion and Improves Chemotherapy Efficacy
por: Krutilina, Raisa I., et al.
Publicado: (2021)

Siderophores: More than Stealing Iron
por: Behnsen, Judith, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling
por: Fatima, Iram, et al.
Publicado: (2019)

Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance
por: Robinson, Prema, et al.
Publicado: (2016)

New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
por: Ciocan-Cartita, Cristina Alexandra, et al.
Publicado: (2020)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2sqkf9nc24l29dgetha3pgvce9